论文部分内容阅读
为研制阿霉素异体脱钙骨基质骨粒骨水泥缓释体 ,并研究分析其体内药物释放特性 ,按Urist等的方法制备异体脱钙骨基质骨粒 ,通过冻干、真空吸附等处理 ,将阿霉素载入其中并与骨水泥按 1∶1比例复合 ,制得阿霉素异体脱钙骨基质骨粒骨水泥缓释体 ,植入家兔股骨粗隆部进行体内药物释放实验。该缓释体可使阿霉素在局部骨组织中缓慢释放达 12周以上 ,4周内维持相对稳定的水平。骨组织中最高浓度是静注相同剂量阿霉素时的 2 9倍 ,但血浆峰值浓度仅为静注组的 1/ 10 ;局部骨组织早期浓度高 ,以后为稳定的低浓度释放。提示该缓释体具有良好的缓释功能 ,能较好地满足骨肿瘤保肢术后局部化疗的要求。
In order to develop doxorubicin allograft decalcified bone matrix bone cement matrix sustained-release material, and to study its in vivo drug release characteristics, according to Urist et al prepared bone demineralized decalcified bone particles by freeze-drying, vacuum adsorption and other treatment, Doxorubicin was loaded into it and compounded with bone cement in the ratio of 1: 1 to prepare doxorubicin allograft decalcified bone matrix bone cement-grafted sustained-release material and implanted into rabbit intertrochanteric part for in vivo drug release experiment. The sustained-release body can make doxorubicin slowly release in local bone tissue for more than 12 weeks, maintaining a relatively stable level within 4 weeks. The highest concentration in bone tissue was 29 times higher than the same dose of doxorubicin, but the plasma peak concentration was only 1/10 in the intravenous group. The local bone tissue had a high early concentration and a stable low concentration release later. Prompted that the sustained-release body has a good sustained-release function, can better meet the requirements of local chemotherapy after limb salvage surgery.